BlackRock Inc. raised its holdings in Recro Pharma Inc (NASDAQ:REPH) by 27.6% in the second quarter, HoldingsChannel.com reports. The fund owned 1,144,988 shares of the specialty pharmaceutical company’s stock after buying an additional 247,559 shares during the quarter. BlackRock Inc. owned approximately 0.06% of Recro Pharma worth $5,747,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new stake in Recro Pharma in the first quarter valued at $139,000. Monarch Partners Asset Management LLC acquired a new stake in Recro Pharma in the second quarter valued at $178,000. GSA Capital Partners LLP acquired a new stake in Recro Pharma in the second quarter valued at $206,000. Algert Global LLC acquired a new stake in Recro Pharma in the second quarter valued at $484,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Recro Pharma in the second quarter valued at $559,000. 54.79% of the stock is owned by institutional investors.
A number of research firms have commented on REPH. Piper Jaffray Companies set a $10.00 target price on Recro Pharma and gave the company a “buy” rating in a report on Thursday. Oppenheimer set a $18.00 price target on Recro Pharma and gave the company a “buy” rating in a research report on Thursday. Zacks Investment Research upgraded Recro Pharma from a “hold” rating to a “strong-buy” rating and set a $8.25 price target for the company in a research report on Wednesday. ValuEngine upgraded Recro Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Janney Montgomery Scott set a $13.00 price target on Recro Pharma and gave the company a “buy” rating in a research report on Monday, October 1st. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Recro Pharma currently has an average rating of “Buy” and a consensus price target of $12.88.
Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.03. Recro Pharma had a negative return on equity of 144.84% and a negative net margin of 75.19%. The business had revenue of $18.28 million during the quarter, compared to analysts’ expectations of $16.77 million. As a group, sell-side analysts anticipate that Recro Pharma Inc will post -2.46 earnings per share for the current fiscal year.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Featured Story: Outstanding Shares, Buying and Selling Stocks
Want to see what other hedge funds are holding REPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recro Pharma Inc (NASDAQ:REPH).
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.